TrialInvestigational new drugs2021
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Clinton Yam et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this papercites it
TrialInvestigational new drugs2021
Clinton Yam et al.PubMed ↗Publisher ↗
No numbers read from the abstract.